Skip to main content
. Author manuscript; available in PMC: 2022 Oct 1.
Published in final edited form as: Eur J Heart Fail. 2021 Jun 6;23(10):1712–1721. doi: 10.1002/ejhf.2207

Table 1.

Baseline characteristics of participants in the main analysis and the ejection fraction sub-cohort stratified by adjudicated heart failure diagnosis during Women’s Health Initiative follow-up

Total cohort (n = 146 817) Total HF (n = 3272) EF sub-cohort (n = 2528)
Age (years), mean (SD) 63.07 (7.20) 68.10 (6.73) 66.49 (6.84)
Ethnicity, n (%)
 American Indian or Alaskan Native 635 (0.4) 17 (0.5) 10 (0.4)
 Asian or Pacific Islander 3921 (2.7) 33 (1.0) 21 (0.8)
 Black or African-American 13 260 (9.1) 375 (11.5) 651 (25.8)
 Hispanic/Latino 5948 (4.1) 78 (2.4) 132 (5.2)
 White 120 984 (82.6) 2721 (83.4) 1693 (67.0)
 Other 1701 (1.2) 37 (1.1) 20 (0.8)
BMI categories, n (%)
 Underweight (<18.5 kg/m2) 1240 (0.9) 28 (0.9) 10 (0.4)
 Normal (18.5–24.9 kg/m2) 49 881 (34.3) 746 (23.0) 450 (17.8)
 Overweight (25–29.9 kg/m2) 50 741 (34.9) 952 (29.4) 764 (30.2)
 Obesity (>30 kg/m2) 43 691 (30.0) 1514 (46.7) 1284 (50.8)
Alcoholic servings/week, mean (SD) 2.36 (4.86) 1.77 (4.44) 1.88 (4.91)
Physical activity (MET-h/week), mean (SD) 12.46 (13.75) 9.14 (11.32) 9.14 (11.78)
Smoking (pack-years), mean (SD) 9.83 (18.33) 15.90 (25.03) 14.20 (22.78)
Mammogram in last 2 years, n (%) 118 591 (83.4) 2470 (78.6) 1803 (71.3)
PCP in last 1 year, n (%) 115 644 (81.5) 2784 (88.1) 1989 (78.7)
Hormone use, n (%) 95 795 (67.1) 1840 (58.2) 1153 (45.6)
Comorbidities, n (%)
 Diabetes mellitus 8279 (5.6) 716 (21.9) 485 (19.2)
 Hypertension 48 425 (33.3) 1926 (59.6) 1371 (54.2)
 Hyperlipidaemia 18 992 (13.8) 678 (22.5) 422 (16.7)
 Cardiovascular disease 22 951 (16.6) 1199 (22.5) 633 (25.0)
Family history, n (%)
 Any cancer 29 003 (20.0) 620 (19.3) 481 (19.0)
 Diabetes mellitus 47 096 (32.2) 1229 (37.7) 1029 (40.7)

BMI, body mass index; EF, ejection fraction; HF, heart failure; PCP, primary care physician; SD, standard deviation.